Hans Gelderblom

53.3k total citations · 8 hit papers
743 papers, 25.3k citations indexed

About

Hans Gelderblom is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hans Gelderblom has authored 743 papers receiving a total of 25.3k indexed citations (citations by other indexed papers that have themselves been cited), including 362 papers in Pulmonary and Respiratory Medicine, 288 papers in Oncology and 129 papers in Molecular Biology. Recurrent topics in Hans Gelderblom's work include Sarcoma Diagnosis and Treatment (217 papers), Gastrointestinal Tumor Research and Treatment (101 papers) and Colorectal Cancer Treatments and Studies (77 papers). Hans Gelderblom is often cited by papers focused on Sarcoma Diagnosis and Treatment (217 papers), Gastrointestinal Tumor Research and Treatment (101 papers) and Colorectal Cancer Treatments and Studies (77 papers). Hans Gelderblom collaborates with scholars based in Netherlands, United States and Germany. Hans Gelderblom's co-authors include Henk‐Jan Guchelaar, Jaap Verweij, Alex Sparreboom, Kees Nooter, Pancras C.W. Hogendoorn, Nielka P. van Erp, Jean‐Yves Blay, Judith V.M.G. Bovée, Ilse Tischer and J.W.R. Nortier and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Hans Gelderblom

714 papers receiving 24.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cremophor EL

2001 1.4k citations Hans Gelderblom et al. European Journal of Cancer profile →
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

2014 814 citations Hans Gelderblom, Patrick Schöffski et al. profile →
A very small porcine virus with circular single-stranded DNA

1982 640 citations Hans Gelderblom et al. profile →
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010 574 citations Hans Gelderblom et al. Annals of Oncology profile →
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

2016 539 citations Patrick Schöffski, Hans Gelderblom et al. profile →
The Clinical Approach Towards Chondrosarcoma

2008 515 citations Hans Gelderblom, Judith V.M.G. Bovée et al. profile →
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

2020 251 citations Jean‐Yves Blay, Hans Gelderblom et al. profile →

Peers

Countries citing papers authored by Hans Gelderblom

Since Specialization

Citations

This map shows the geographic impact of Hans Gelderblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Gelderblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Gelderblom more than expected).

Fields of papers citing papers by Hans Gelderblom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Gelderblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Gelderblom. The network helps show where Hans Gelderblom may publish in the future.

Co-authorship network of co-authors of Hans Gelderblom

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Gelderblom. A scholar is included among the top collaborators of Hans Gelderblom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Gelderblom. Hans Gelderblom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy 2026 ·The Breast ·(unknown), Laura Kervezee, Claudia A. Bargon, Daniel J. Evers, (unknown), (unknown), (unknown), Hans Gelderblom, Jacques Neefjes, (unknown), (unknown)	0
2	The Impact of Chemotherapy and Body Mass Index on Cancer‐Related Fatigue in Colon Cancer Patients: A PROFILES ‐Registry Study 2025 ·Cancer Medicine ·(unknown), Floortje Mols, Laura Kervezee, Niels H. Chavannes, Hans Gelderblom, Jacques Neefjes, Chris Hinnen	2
3	Efficacy and Toxicity of Bevacizumab in Children with NF2-Related Schwannomatosis: A Systematic Review 2025 ·Cancers ·(unknown), J.E. Schopman, Radboud W. Koot, Hans Gelderblom, (unknown), (unknown), Jeroen C. Jansen, Erik F. Hensen	1
4	MANEUVER: A Phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients 2024 ·Future Oncology ·(unknown), Vinod Ravi, (unknown), (unknown), (unknown), (unknown), Hans Gelderblom	7
5	DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients 2024 ·BMJ Open ·(unknown), Frederiek van den Bos, Marije Slingerland, (unknown), Gerrit‐Jan Liefers, Wilbert B. van den Hout, Marta Fiocco, Arie J. Verschoor, (unknown), Cynthia Holterhues, Danny Houtsma, Anouk Jochems, (unknown), Leti van Bodegom‐Vos, Simon P. Mooijaart, Hans Gelderblom, Frank M. Speetjens, Nienke A. de Glas, Johanneke E. A. Portielje	0
6	1915MO Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study 2023 ·Annals of Oncology ·(unknown), (unknown), Ingrid M.E. Desar, Hans Gelderblom, (unknown), Anna K.L. Reyners, Neeltje Steeghs, Winette T.A. van der Graaf, Olga Husson	1
7	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) 2023 ·Annals of Oncology ·Karin Verkerk, (unknown), Laurien J. Zeverijn, Birgit S. Geurts, (unknown), (unknown), Paul Roepman, Anne M.L. Jansen, Vincent van der Noort, Egbert F. Smit, Ann Hoeben, Lizza Hendriks, Carla M.L. van Herpen, Berber Piet, (unknown), Sayed M.S. Hashemi, Hans Gelderblom, Henk M.W. Verheul, Emile E. Voest, J. De Langen	3
8	1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine 2023 ·Annals of Oncology ·Hans Gelderblom, Anders Edsjö, (unknown), Ulrik Lassen, Åslaug Helland, (unknown), Bettina Ryll, Iwona Ługowska, Jean‐Yves Blay, Ragnhild Sørum Falk, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Katriina Peltola, Albrecht Stenzinger, Eduard Vrdoljak, Júlio Oliveira, (unknown), Henk M.W. Verheul, Emile E. Voest, Kjetil Taskén	1
9	Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study 2022 ·JMIR Formative Research ·(unknown), (unknown), Suzan Verberne, Ingrid M.E. Desar, Olga Husson, Winette T.A. van der Graaf, (unknown), Anna K.L. Reyners, Neeltje Steeghs, (unknown), G. van Oortmerssen, Hans Gelderblom, Wessel Kraaij	1
10	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors breakdown → 2021 ·Clinical Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing	257
11	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA” 2021 ·European Journal of Cancer ·Patrick Schöffski, Maud Toulmonde, Anna Estival, Gloria Marquina, (unknown), Mehdi Brahmi, Neeltje Steeghs, Vasilios Karavasilis, Jacco J. de Haan, Agnieszka Woźniak, Sophie Cousin, Marta Doménech, Judith V.M.G. Bovée, Céline Charon‐Barra, Sandrine Marréaud, Saskia Litière, (unknown), (unknown), Hans Gelderblom	10
12	Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials 2019 ·Clinical Cancer Research ·Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean‐Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. van Erp, Hans Gelderblom, Winette T.A. van der Graaf, Alessandro Gronchi	64
13	Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma 2018 ·Clinical Cancer Research ·David G.P. van IJzendoorn, Stefan Sleijfer, Hans Gelderblom, Ferry A.L.M. Eskens, Geert J.L.H. van Leenders, Károly Szuhai, Judith V.M.G. Bovée	35
14	Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies 2018 ·Clinical Cancer Research ·(unknown), Olivia Orozco, Tinya J. Abrams, (unknown), (unknown), Jayesh Desai, Hilmar Ebersbach, Hans Gelderblom, Keith Hoffmaster, Emma Lees, Heiko Maacke, (unknown), (unknown), Si Tuen Lee-Hoeflich	18
15	Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib 2015 ·Cancer ·Peter Reichardt, Yoon‐Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S. Rosen, Beatrice Seddon, Şuayib Yalçın, Hans Gelderblom, Charles C. Williams, Elena Fumagalli, Guido Biasco, Herbert I. Hurwitz, (unknown), Kolette D. Fly, Ewa Matczak, (unknown), María José Lechuga, George D. Demetri	85
16	Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, F. Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, Fortunato Ciardiello	94
17	Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab 2011 ·Clinical Cancer Research ·Jan Pander, Moniek Heusinkveld, Tahar van der Straaten, Ekaterina S. Jordanova, Renée Baak-Pablo, Hans Gelderblom, Hans Morreau, Sjoerd H. van der Burg, Henk‐Jan Guchelaar, Thorbald van Hall	87
18	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib 2010 ·Clinical Cancer Research ·Astrid A.M. van der Veldt, Karel Eechoute, Hans Gelderblom, Jourik A. Gietema, Henk‐Jan Guchelaar, Nielka P. van Erp, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Ron H.J. Mathijssen, Judith A.M. Wessels	127
19	The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab 2008 ·Ghent University Academic Bibliography (Ghent University) ·Sabine Tejpar, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, Gert De Hertogh, Wendy De Roock, Johannes Nippgen, (unknown), Christopher Stroh, (unknown)	4
20	Cerebrospinal Fluid-Infiltrating CD4 ⁺ T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis 2006 ·Infection and Immunity ·Jan D. Lünemann, Hans Gelderblom, Mireia Sospedra, Jacqueline A. Quandt, Clemencia Pinilla, Adriana Marques, Roland Martinꝉ	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact